

Contact Carl Berke For More Information [Carl@Berkesearch.com](mailto:Carl@Berkesearch.com)

- **04.24.23 - Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer (PR)**
  - Dr. Dayno joined Harmony as Chief Medical Officer and Executive Vice President when the company was founded in 2017 and has been serving as Interim President and CEO since January 6, 2023. Harmony Board Chairman, Jeff Aronin, noted that Dr. Dayno, a nationally recognized neuroscience expert, has been a valuable member of the Company's inaugural executive management team since 2017. He played a critical role in the FDA approval of Harmony's key asset, WAKIX<sup>®</sup> (pitolisant), and helped to shape commercial strategy
- **04.23.23 - ImmunoGen Appoints Isabel Kalofonos as SVP & Chief Commercial Officer (PR)**
  - Ms. Kalofonos joins ImmunoGen from Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. She also led all commercial franchises of prescription products. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise - a 2.5 billion dollar business. In this role she oversaw the global blockbuster launch of TAKHZYRO<sup>®</sup> (lanadelumab-flyo). Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals. Ms. Kalofonos received a BS from Pontificia Universidad Javeriana and an MBA from Babson College.
- **04.21.23 - LianBio Promotes Pascal Qian to Chief Commercial Officer (PR)**
  - LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial Officer. He will continue to also serve as the company's China General Manager. Pascal Qian has more than 25 years of experience in the China biopharmaceutical industry and a robust track record of driving revenue growth and building successful commercial teams. He has launched multiple drugs in the region, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair. Mr. Qian has served as LianBio's China General Manager since July 2021. In his expanded role as Chief Commercial Officer, he will lead the company's commercial strategy and readiness, in addition to managing China operations.
- **04.20.23 - Heron Therapeutics Announces Commercial Leadership Changes (PR)**
  - Heron, a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and Marketing, Acute Care, effective April 24, 2023. Mr. Grillot brings more than two decades of hospital experience, most recently serving as a senior sales executive at CHIESI USA.
- **04.20.23 - Abata Therapeutics Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer (PR)**
  - Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics. Previously, he held leadership roles in early clinical development at Janssen Biopharma, Merck Research Laboratories, and Genentech, where he advanced preclinical, pre-investigational new drug (IND) and early clinical programs. In these roles, he focused on advancing science and creating infrastructures that enable cross-functional collaboration and scientific advancement. Abata cofounder and Third Rock Ventures Venture Partner Richard Ransohoff, M.D., has been the company's interim CMO since its founding, and with Dr. Dragone's appointment, Dr. Ransohoff will move into an advisory role.
- **04.19.23 - Astria Therapeutics Names Andrea Matthews Chief Business Officer (PR)**
  - Ms. Matthews will be responsible for leading the company's Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy functions. Most recently, she served as Senior Vice President, Corporate Affairs at Astria, since October 2020. Previously, she served as Vice President, Corporate Affairs since 2017, Executive Director, Corporate Affairs since 2015, and Senior Director, Operations and Corporate Development since 2014. Prior to joining Astria, Ms. Matthews served as Vice President, Operations and Alliance Management/Commercial Operations at Selventa (formerly Genstruct) from 2010 and Director, Alliance Management from 2009. From 2003 to 2009, Ms. Matthews held a series of roles with increasing responsibility at Genstruct. Ms. Matthews holds an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management and a B.A. in Biochemistry and Molecular Biology from Boston University.
- **04.19.23 - Agios Appoints Jeffrey Capello to Board of Directors (PR)**
  - Mr. Capello brings to Agios deep operational and financial expertise in the healthcare and life science sectors. Most recently, he was the chief financial officer for Biogen, where he partnered with the executive team to achieve consistent and predictable financial outcomes while enhancing the R&D pipeline and implementing a disciplined capital allocation process. Earlier in his career, Mr. Capello served as a chief financial officer of several leading healthcare companies, including Boston Scientific, PerkinElmer, Ortho Clinical Diagnostics and Beacon Health Options. He has served as a member of the board of directors and chair of the audit committee of several early-stage, publicly held life sciences companies, including Sirtris, OvaScience and Flex Pharma

- **04.18.23 - Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors (PR)**
  - Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure. During his tenure at Merck & Co., Mr. Johnson held numerous senior leadership roles, primarily within commercial operations, sales, and marketing, across a wide range of therapeutic categories. He led large scale regional, national, and global sales and marketing organizations worth over \$3 billion in annual revenue, including in his role as Vice President of the U.S. Human Health East Commercial Operations Group for the Primary Care Sales division and prior to that, Global Brand Leader for Merck's Migraine franchise where he successfully led product launches in various countries around the world. Most recently, Mr. Johnson was the Chief Learning Officer for Merck's Global Learning and Development department
- **04.17.23 - Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances (PR)**
  - **Ralph Kern, M.D., MHSc**, is Chief Medical Officer at Cognito Therapeutics. He was previously President, Chief Medical Officer at BrainStorm Cell Therapeutics and SVP, Head Global Medical at Biogen, VP, Head US Neuroscience Medical Unit at Novartis and General Manager Fabrazyme Biologics franchise at Genzyme. Prior to joining the biotechnology industry, Ralph was head of the academic neurology program at the University of Toronto and led the clinical neurophysiology department at Mount Sinai Hospital in Toronto.
  - **Kim Kwan** is Chief Technology Officer at Cognito Therapeutics. Kim joined Cognito in 2018 and was previously the Vice President of Engineering. Kim is leading device development and manufacturing operations to support Cognito's clinical studies and product commercialization. His focus at Cognito is to build a system platform that can be scalable to the nearly 5 million patients living with mild-to-moderate Alzheimer's Disease and to potentially support treatments for a broad range of neurodegenerative disorders.
- **04.18.23 - Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer (PR)**
  - Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD). Prior to joining Ocelot Bio, Dr. Kjems was the chief medical officer at Cyclo Therapeutics where she led its global program evaluating Trappsol® Cyclo™ in Alzheimer's and rare disease. Earlier in her career, Dr. Kjems was essential in bringing Albireo Pharma's drug Bylvay® through its Phase 3 program in progressive familial intrahepatic cholestasis (PFIC) to FDA and EMA approvals, as well as launching pivotal Phase 3 trials for Bylvay in biliary atresia and Alagille syndrome. She has also held various positions of increasing responsibility at Aldeyra Therapeutics, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson and Novartis.
- **04.13.23 - Eiger BioPharmaceuticals Strengthens Management Team with New Appointments (PR)**
  - **Mr. Kachioff** is highly experienced in corporate finance, investor relations, capital formation, corporate governance and manufacturing accounting and systems. He has over 30 years of life sciences industry experience and is currently a consulting CFO with Danforth Advisors, with whom Eiger has contracted for his services. He recently served as interim CFO at Aduro Biotech (now Chinook Therapeutics), a publicly-traded, clinical-stage cancer immunotherapy company and previously served as CFO at GenomeDx Biosciences (now Veracyte) and Biocept, two providers of novel cancer diagnostic services. Prior to that, he was CFO at Althea Technologies (now Ajinomoto Bio-Pharma), a pharmaceutical contract manufacturer. Mr. Kachioff has served as CFO at Microlslet, a publicly-traded biotech company developing cell transplant therapies for insulin-dependent diabetes and was Director of Finance at Cutera, where he prepared the company for the commercial launch of its first product and its initial public offering. M
  - **Mr. Vollins** is an experienced public company, biotechnology, and healthcare compliance attorney with significant executive leadership experience and a focus on scaling high-quality biotech companies and best-in-class compliance programs. During his 30-year legal career, he has worked for several global biotechnology companies in roles of increasing responsibility. Prior to joining Eiger, Mr. Vollins was General Counsel, Chief Compliance Officer and Corporate Secretary at BioDelivery Sciences International, Inc. Prior to that, he was General Counsel, Chief Compliance Officer and Corporate Secretary at Bio Products Laboratory Limited. Mr. Vollins also served in a variety of roles with increasing responsibility at Grifols Inc., Talecris Biotherapeutics, Inc. and Pfizer Inc.
- **04.15.23 - Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources (PR)**
  - Jasper is a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimens. Mr. Ford joins Jasper from Tricida, where he served as Senior Vice President for Human Resources and Operations reporting directly to the CEO. In this role he helped build the human resource and other business functional teams following the company's initial public offering. Prior to Tricida, Mr. Ford was with Jazz Pharmaceuticals, where he served in roles such as Global Head of Human Resource Business Partners and Human Resource Business Partner for Research and Development. Prior to his time at Jazz, Mr. Ford served as Associate Director of Worldwide Human Resource Operations for Gilead Sciences, a position he held following a series of roles of increasing responsibility in Gilead's global organization. Prior to Gilead, Mr. Ford was a Human Resource Manager at GlaxoSmithKline